FIELD: medicine; pharmaceutics.
SUBSTANCE: group of inventions relates to pharmaceutics. Invention discloses the use of the sulphonylhydroxamic acid-based compound for treating inflammatory pulmonary disorders and for treating fibrotic disorders.
EFFECT: group of inventions provides treating inflammatory pulmonary disorders and fibrotic disorders by inhibiting HDAC.
7 cl, 18 dwg, 4 tbl, 15 ex
Authors
Dates
2025-01-20—Published
2021-09-03—Filed